Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 11,650
+390 (3.46%)
At close: Feb 6, 2026
Prestige BioPharma Market Cap
Prestige BioPharma has a market cap or net worth of 140.02 billion as of February 6, 2026. Its market cap has decreased by -24.05% in one year.
Market Cap
140.02B
Enterprise Value
222.68B
Revenue
14.41B
Ranking
n/a
PE Ratio
44.40
Stock Price
11,650.00
Market Cap Chart
Since May 28, 2021, Prestige BioPharma's market cap has decreased from 360.58B to 140.02B, a decrease of -61.17%. That is a compound annual growth rate of -18.23%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 6, 2026 | 140.02B | -9.34% |
| Dec 30, 2025 | 154.45B | -14.96% |
| Dec 30, 2024 | 181.61B | 59.39% |
| Dec 28, 2023 | 113.94B | 29.33% |
| Dec 29, 2022 | 88.10B | -64.84% |
| Dec 30, 2021 | 250.60B | -30.50% |
| May 28, 2021 | 360.58B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| HLB Therapeutics | 241.80B |
| Genexine | 201.02B |
| MedPacto | 193.65B |
| Macrogen | 188.10B |
| ENCell | 181.90B |
| GeneOne Life Science | 170.32B |
| IMB Dx | 122.52B |
| iNtRON Biotechnology | 115.42B |